Protalix BioTherapeutics, Inc. (PLX)
-NYSE MKT | Prev Close: | 5.23 |
|---|
| Open: | N/A |
|---|
| Bid: | N/A |
|---|
| Ask: | N/A |
|---|
| 1y Target Est: | 6.00 |
|---|
| Beta: | 1.24 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | N/A - N/A |
|---|
| 52wk Range: | 4.71 - 6.80 |
|---|
| Volume: | 0 |
|---|
| Avg Vol (3m): | 175,364 |
|---|
| Market Cap: | 482.12M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.11 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Protalix signs supply deal with Brazilian govtAP(Wed, Jun 19)
- Protalix BioTherapeutics and Brazil's Ministry of Health Enter Into Supply and Technology Transfer Agreement for UPLYSO(TM) (alfataliglicerase) in BrazilGlobeNewswire(Wed, Jun 19)
- PROTALIX BIOTHERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other EventsEDGAR Online(Tue, Jun 18)
- American Generics Can't Touch This $8 Billion Drug (Yet)at Motley Fool(Mon, Jun 17)
- Protalix BioTherapeutics to Host Analyst Event in New York CityGlobeNewswire(Wed, Jun 12)
- PROTALIX BIOTHERAPEUTICS, INC. Files SEC form 8-K, Regulation FD DisclosureEDGAR Online(Wed, Jun 12)
- 4 Longshot Stocks to Invest Inat Motley Fool(Thu, May 30)
- Protalix BioTherapeutics to Present at Three Upcoming Healthcare ConferencesGlobeNewswire(Wed, May 29)
- PLX July Options Begin Tradingat TheStreet(Mon, May 20)
- PROTALIX BIOTHERAPEUTICS, INC. FinancialsEDGAR Online Financials(Fri, May 17)
- Protalix Bio gets vote of confidenceoptionMONSTER(Tue, May 14)
- PROTALIX BIOTHERAPEUTICS, INC. Files SEC form 10-Q, Quarterly ReportEDGAR Online(Thu, May 9)
- Protalix BioTherapeutics to Present at the Oppenheimer 14th Annual Israeli ConferenceGlobeNewswire(Wed, May 8)
- Boris Peaker, Executive Director and Senior Analyst at Oppenheimer & Co. Inc., Interviews with The Wall Street Transcript: Finding Innovation in Biotechnology for Cell Therapy, Oncology and Orphan DrugsWall Street Transcript(Wed, May 1)
- J.C. Penney Lands a Loan, Protalix Rides on Approval, and 3 Other Hot Stocksat Wall St. Cheat Sheet(Mon, Apr 29)
Key Statistics
| Forward P/E (1 yr): | 523.00 |
|---|
| P/S (ttm): | 13.91 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -0.17 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.04 |
|---|
| Mean Recommendation*: | 2.5 |
|---|
| PEG Ratio (5 yr expected): | -1.23 |
|---|
Business Summary
Protalix BioTherapeutics, Inc., a biopharmaceutical company, together with its subsidiary, Protalix Ltd., focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression sy...
View More 
1.35%